Aprogen, Inc

As of June 30, 2026, Aprogen, Inc carries a market capitalization of 52.60B, placing it among publicly traded companies globally. Its enterprise value stands at 544.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Aprogen, Inc has 21.04M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.29, and the price-to-book ratio stands at 0.87.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.92 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 544.58B versus a market cap of 52.60B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Aprogen, Inc maintains a current ratio of 0.83, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.80, indicating elevated leverage, while an interest coverage ratio of 3.48 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Aprogen, Inc posted a negative return on equity (ROE) of -82.23, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.27, reflecting losses generated across the asset base. The company generates approximately 452.08M in revenue per employee across its workforce of 307.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.73 indicates how many times Aprogen, Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Aprogen, Inc recorded 1.36B in income tax expense. The company reported a pretax loss of -137.28B and -83.53B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Aprogen, Inc's stock has declined approximately 79.77% over the past 52 weeks. The 50-day moving average sits at 2,156.52, while the 200-day moving average is 5,633.03.

Over the twelve months ended June 30, 2026, Aprogen, Inc generated 138.90B in revenue and converted that into -83.53B in net income, yielding earnings per share of -8,713.89. EBITDA reached -68.99B, while operating income came in at -92.25B.

As of June 30, 2026, Aprogen, Inc holds 43.16B in cash and equivalents against 181.45B in total debt, resulting in a net debt position of 141.91B. Total book value stands at 60.54B, with working capital of -32.23B providing operational flexibility.

Aprogen, Inc produced -62.79B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -26.91B in capital expenditures, free cash flow totaled -89.71B - equivalent to -5,638.40 per share.

Over the twelve months ended June 30, 2026, Aprogen, Inc posted a gross margin of 26.60, reflecting its pricing power and cost economics. The operating margin of -66.42 and net profit margin of -60.14 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Aprogen, Inc paid dividends of -NaN per share. The dividend payout ratio of -NaN indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -225.54: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 19.45, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Aprogen, Inc shareholders.

Aprogen, Inc's most recent stock split took place on May 8, 2026 with a 15:1 split ratio.

As of June 30, 2026, Aprogen, Inc has an Altman Z-Score of -1.21, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.